Funding Supports Pharnext’s Phase 3 Trial of PXT3003

Funding Supports Pharnext’s Phase 3 Trial of PXT3003

288135

Funding Supports Pharnext’s Phase 3 Trial of PXT3003

Pharnext has received €11 million ($13.3 million) in funding to support a Phase 3 trial investigating its investigational therapy PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A). The proceeds include €6 million ($7.2 million) from existing shareholders and €5 million ($6 million) from European investors. The upcoming PREMIER trial (NCT04762758) is set to begin in March and to enroll 350 CMT1A patients at 50 sites around the world. More information about contacts and…

You must be logged in to read/download the full post.